YOLFTbeta
NX

Nexalis Therapeutics Ltd

NX1 · AU · Healthcare / Biotechnology

0.008AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.008
Open0.008
Day Range0.008 – 0.008
52-Week Range0.007 – 0.03
Volume1.08M
Market Cap3.80M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.16
50-Day Avg0.0111
200-Day Avg0.0183

About

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Darryl Davies B.Sc.
  • Headquarters505 Little Collins Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://inhalerx.com.au

Leadership

  • Mr. Darryl Davies B.Sc.CEO & Interim Executive Director
  • Dr. Robert Jenny B.A., B.Sc., Ph.D.Chief Scientific Officer
  • Mr. James Stephen Barrie CPACompany Secretary & Director
  • Mr. Greg HammondChief Financial Officer
  • Mr. Srinivasa Rao SuryadevaraExecutive Vice President · b. 1969

Financials

Income Statement

Currency: AUD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue167.30K51.85K1.21M405.46K992.17K
Growth (%)--69.01%+2226.09%-66.38%+144.70%
Cost of Revenue115.23K0---
Gross Profit52.07K51.85K---
Gross Margin31.12%100.00%---
Operating Expense1.18M1.98M---
Operating Income-1.13M-1.93M-1.44M-1.28M-1.48M
Operating Margin-672.98%-3716.59%-118.99%-314.62%-149.40%
EBITDA--1.95M-1.44M-1.12M-1.48M
EBITDA Margin--3767.75%-118.99%-276.59%-149.40%
Net Income-1.11M-1.93M-1.44M-1.21M-1.62M
Net Income Margin-664.15%-3716.59%-119.67%-298.27%-163.16%
Interest Expense--8.11K87.92K136.50K
Interest Expense % of Total Revenue--0.67%21.68%13.76%

Balance Sheet

Currency: AUD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.95M2.26M1.58M712.40K1.43M
Total Liabilities253.34K355.32K911.41K445.26K2.05M
Total Equity2.68M1.90M665.47K267.14K-619.41K
Cash2.80M2.13M715.82K194.92K436.90K
Net Debt----304.38K

Cash Flow

Currency: AUD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---1.96M-368.77K-888.17K
Investing Cash Flow--000
Financing Cash Flow2.26M1.18M544.29K-152.14K1.13M
Capital Expenditure25.09K175000
Free Cash Flow-1.17M-1.85M-1.96M-368.77K-888.17K
FCF to OCF--100.00%100.00%100.00%

Key Statistics & Ratios

Market Cap3.80M
Enterprise Value2.21M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.56
Price / Book8.55
EPS-0.01
Book Value-0.007
Revenue (TTM)1.07M
Gross Profit (TTM)1.07M
Profit Margin-193.64%
Operating Margin-186.87%
Return on Equity0.00%
Return on Assets-75.98%
Shares Outstanding253.04M
Shares Float79.90M
Beta0.16
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%